Drug profile · INN
nifedipine
APO-NIFEDIPINE XR
nifedipine (APO-NIFEDIPINE XR) is a voltage-gated l-type calcium channel blocker. Associated with Apotex Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
Drug details — nifedipine
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 1
- Programs
- 5
- Data quality
- 0.89
Quick answer
nifedipine (APO-NIFEDIPINE XR) is a voltage-gated l-type calcium channel blocker. Associated with Apotex Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Voltage-gated L-type calcium channel blocker
Primary target: Voltage-gated L-type calcium channel
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| TGA | approved | — |
| NMPA | clinical trials | — |
Pipeline programs
Related & competitor drugs
Related patents
Frequently asked questions
What is nifedipine?
nifedipine (APO-NIFEDIPINE XR) is a voltage-gated l-type calcium channel blocker. Associated with Apotex Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for nifedipine?
APO-NIFEDIPINE XR is a marketed brand name for nifedipine. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of nifedipine?
nifedipine has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.